Insider · CIK 0001748265
Christopher Posner
Files at TVRD (Tvardi Therapeutics, Inc.). First filing Nov 6, 2024, latest Mar 4, 2025.
In brief
Christopher Posner files SEC Form 4 as CEO, president and director at TVRD (Tvardi Therapeutics, Inc.). Since Nov 6, 2024, Christopher Posner has reported 0 open-market buys worth $0 and 3 open-market sells worth $5,589, the latest filed on Mar 4, 2025.
A track record needs three past buys with six months of prices behind them; Christopher Posner has 0, so none is measured yet.
The newest scored trade: sold $2,769 of TVRD on Feb 28, 2025, filed Mar 4, 2025, scored 13 (weak), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TVRD: Tvardi Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 13Weak | Tvardi Therapeutics, Inc. | $2,769 583 shares | -4% | - | |
| 5Weak | Tvardi Therapeutics, Inc. | $1,756 372 shares | -3% | - | |
| 5Weak | Tvardi Therapeutics, Inc. | $1,064 3,668 shares | -2% | - |
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | TVRD Tvardi Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -583 | $4.75 | $2,769 | 13,109 | Mar 4, 2025 |
| Feb 4, 2025 | TVRD Tvardi Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -372 | $4.72 | $1,756 | 13,692 | Feb 6, 2025 |
| Nov 4, 2024 | TVRD Tvardi Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -3,668 | $0.29 | $1,064 | 168,768 | Nov 6, 2024 |
Questions about Christopher Posner
Answered from the filings on this page, as of the latest one.
Is Christopher Posner buying or selling?
Not in the last 12 months. Christopher Posner's latest open-market trade on SEC Form 4 was sold $2,769 of TVRD on Feb 28, 2025.
How did Christopher Posner's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Posner has 0.
Where does Christopher Posner file Form 4?
Christopher Posner has filed Form 4 at TVRD (Tvardi Therapeutics, Inc.) as PRESIDENT AND CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.